ChemoCentryx v. Annora Pharma: Avacopan Patent Case Consolidated
ChemoCentryx filed suit in New Jersey District Court against Annora Pharma over generic avacopan capsules (TAVNEOS® 10 mg), asserting two patents. After 101 days, the action was consolidated with a parallel case into Lead Action No. 2:26-cv-00556 to streamline litigation.
TAVNEOS® avacopan patents at issue as generic challenge consolidated
ChemoCentryx, Inc. filed this patent infringement action on 9 February 2026 in the New Jersey District Court against Annora Pharma Private, Ltd., asserting US11603356B2 and US11951214B2 in connection with Annora's proposed generic avacopan capsules, oral, 10 mg — the active ingredient in ChemoCentryx's branded product TAVNEOS®.
The recorded Basis of Termination is 'Case Consolidated.' The docket order reflects a stipulation among ChemoCentryx, Annora, and a third party identified as Zydus, agreeing to consolidate this action with Civil Action No. 2:26-cv-00556 for all purposes — including discovery, case management, and trial — with all future filings to be made in that Lead Action.
The consolidation after only 101 days suggests that parallel generic-entry challenges by multiple ANDA filers prompted a joint efficiency decision. The substantive merits of the patent infringement claims remain unresolved and will proceed in the Lead Action. The specific terms governing each party's rights going forward are not disclosed in the available record beyond what the stipulation states.
See Complete Case & Patent Analysis →Filing to Case Consolidated in 101 days
101 days from filing to consolidation order
US11603356B2 & US11951214B2 — avacopan formulation patents
Any company developing oral avacopan formulations, C5aR inhibitor capsule products, or related complement pathway therapeutics should evaluate freedom-to-operate against both asserted patents. The active multi-defendant ANDA litigation confirms ChemoCentryx is actively enforcing this estate. Generic manufacturers, co-formulation partners, and biosimilar-adjacent developers face meaningful infringement risk until these patents expire or are invalidated.
Official order — verbatim text
The stipulation reflects a procedural consolidation rather than any merits adjudication. ChemoCentryx, Zydus, and Annora jointly agreed to merge this action with the Lead Action to conserve judicial resources, leaving all substantive patent infringement and validity questions to be resolved in the consolidated proceeding.
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | CHEMOCENTRYX, INC. | Company | /Search in Eureka ↗ |
| Defendant | Annora Pharma Private, Ltd. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Jessica K. Formichella | Attorney | Counsel for CHEMOCENTRYX, INC.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for CHEMOCENTRYX, INC.Search in Eureka ↗ |
| Plaintiff counsel | Marc D. Haefner | Attorney | Counsel for CHEMOCENTRYX, INC.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O'Reilly Falanga LLP | Law Firm | Representing CHEMOCENTRYX, INC.Search in Eureka ↗ |
| Defendant counsel | Jakob Benjamin Halpern | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant law firm | Saiber LLC | Law Firm | Representing Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the avacopan and complement inhibitor IP space
This case surfaces active patent enforcement and competitive generic pressure around ChemoCentryx's avacopan estate — signalling key trends in C5aR inhibitor R&D and formulation IP.
ChemoCentryx's avacopan patent family: continuation risk and expiry map
US11603356B2 and US11951214B2 are linked to application lineage rooted in avacopan formulation development. Monitoring ChemoCentryx's continuation filing activity in this family can reveal whether additional patent layers are being built to extend exclusivity past the current estate — a critical signal for any generic or biosimilar developer.
Portfolio continuationsFiling trends in oral complement C5aR inhibitor formulations
Avacopan's commercial success as the first oral C5aR inhibitor has likely triggered follow-on innovation in complement pathway modulation. Tracking patent filing trends in oral C5aR/C5a receptor inhibitor formulations — particularly from pharma and biotech players in rare disease nephrology — can identify emerging competitive threats and whitespace for next-generation therapeutics.
C5aR inhibitor trendsAnnora Pharma's patent portfolio in generic formulation technologies
Annora Pharma's willingness to challenge two formulation patents simultaneously — alongside Zydus — suggests confidence in their ANDA formulation approach. Reviewing Annora's own patent filings in oral solid dosage forms and specialty generic formulations may reveal the technical differentiation they are relying on to design around ChemoCentryx's claims.
Generic formulation patentsAdjacent C5a pathway targets: innovation whitespace near avacopan
With generic challenges now active, the avacopan space faces near-term IP uncertainty. Adjacent innovation opportunities include alternative C5a receptor subtypes, combination formulations for ANCA-associated vasculitis, and novel oral delivery mechanisms for complement inhibitors — areas where filing activity remains comparatively lower and differentiated IP positions may still be established.
Complement pathway whitespaceSimilar Hatch-Waxman ANDA cases involving C5aR inhibitor and rare disease patents
Explore parallel and related Hatch-Waxman ANDA patent disputes in New Jersey District Court involving specialty pharmaceutical formulation patents in the rare disease space.
What this case signals for the avacopan and C5aR inhibitor IP landscape
Multiple simultaneous generic challenges to TAVNEOS® suggest the avacopan patent estate is a focal point for Hatch-Waxman litigation strategy.
Parallel ANDA filers signal coordinated generic market entry strategy
The consolidation with Zydus's separate action (No. 2:26-cv-00556) confirms at least two generic manufacturers are pursuing simultaneous ANDA challenges to TAVNEOS®. This pattern typically signals that generics view the patent estate as beatable, or commercially attractive enough to litigate aggressively.
Both asserted patents remain in active dispute — no merits resolution yet
US11603356B2 and US11951214B2 have not been adjudicated on validity or infringement in any public record available here. Companies in the C5aR inhibitor space or with avacopan exposure should monitor the Lead Action for claim construction, validity challenges, and any IPR filings.
CHEMOCENTRYX v Annora — key questions answered
The case was terminated by consolidation. The New Jersey District Court action (No. 2:26-cv-01279) was merged with Lead Action No. 2:26-cv-00556 for all purposes, including discovery, case management, and trial. No merits ruling on patent infringement or validity has been issued in this action.
ChemoCentryx asserted US11603356B2 (application no. US17/091001) and US11951214B2 (application no. US17/545878) against Annora's proposed generic avacopan capsules, oral, 10 mg — the active ingredient in ChemoCentryx's branded TAVNEOS® product.
According to the stipulation in the docket, ChemoCentryx, Annora, and Zydus jointly agreed to consolidate the two actions to conserve judicial resources. The order specifies that No. 2:26-cv-00556 is the Lead Action and all future filings are to be made there.
The stipulation names Zydus as a party alongside ChemoCentryx and Annora, indicating a parallel ANDA action (No. 2:26-cv-00556) was filed by or against Zydus asserting the same or related patents over avacopan. The consolidated proceeding will address both defendants' challenges together. The specific claims against Zydus are not detailed in the available record for this action.
No. Consolidation does not dismiss the underlying infringement claims. The substantive allegations under US11603356B2 and US11951214B2 against Annora Pharma remain live and will be litigated in Lead Action No. 2:26-cv-00556. The termination of Case No. 2:26-cv-01279 is a procedural docket closure, not a merits resolution.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.